A source-checked guide to the legacy storefront shutdown, the EU site’s current product information, tirzepatide science, FDA rules, and laboratory documentation.

Editorial illustration from the source article; not a photograph of a verified facility or product batch.

QUICK ANSWER The original peptidesciences.com retailer says it discontinued sales. EU Peptide Sciences is a separate, independent research supplier at eupeptidesciences.com, which advertised a Tirzepatide 10mg listing and links to 5mg and 15mg options on 8 October 2026. The two companies are not the same, and the EU seller should not be described as the former brand’s successor. FDA approval of specific tirzepatide medicines does not extend to independent research vials. [1][2][3][4]

For former customers, the query is not simply about a molecule. It asks whether the familiar supplier still exists, whether its older tirzepatide pages have vanished, and what an apparently new EU-branded website has to do with the old name. Those questions became more prominent after the original Peptide Sciences storefront announced it had voluntarily stopped selling research products. [1]

The October 2026 US Ahrefs export estimates about 300 searches a month for “peptide sciences tirzepatide”, 150 for “tirzepatide peptide sciences”, and 40 for “peptide sciences tirzepatide 10mg”. A smaller query, “why did peptide sciences stop selling tirzepatide,” registers around 20. These are third-party estimates, not proof that the searches refer to a single company or that searchers intend to purchase anything. [A]

The essential distinction: an active product page, a historical brand relationship, and regulatory permission are three different questions. They should not be collapsed into one claim.

Verification status	Finding
Documented	The original domain displays a shutdown notice.
Documented	The EU site publishes a Tirzepatide 10mg page.
Company-reported	Independent batch testing and COAs are advertised.
Not established	Exact removal date of historic tirzepatide listings.
Independent	EU Peptide Sciences is a separate company, not the original seller.

 

What happened to the original tirzepatide listings?

The original peptidesciences.com page currently says the company decided to voluntarily close operations and discontinue sales. It expressly retains rights to its brand and warns against sites representing themselves as authorized affiliates or successors. Its current notice does not provide a product-by-product removal log or an explanation specifically about tirzepatide. [1]

Older branded tirzepatide searches and references indicate sustained customer interest in the product category. However, the available primary-source material does not establish exactly when an original Tirzepatide 5mg, 10mg, or 15mg listing was last sold, whether a particular strength was delisted ahead of the wider shutdown, or why any such decision was made. This article therefore does not invent an old price list, product inventory, or a day-by-day retirement timeline.

It would also be inaccurate to announce that the FDA ordered this named vendor to shut down. FDA action around compounded and unapproved GLP-1 drugs is relevant industry context, but no verified public evidence reviewed here identifies that action as the specific cause of this company’s closure.

Date	Public event (not an established closure cause)
December 2024	FDA reaffirmed that the tirzepatide shortage was resolved.
March 2025	Post-shortage compounding transition period ended.
February 2026	FDA announced intensified action concerning unapproved GLP-1 drugs.
2026	Original Peptide Sciences domain displayed its shutdown notice.

 

What EU Peptide Sciences actually lists in October 2026

At the time of review, the EU site’s Peptide Sciences Tirzepatide 10mg page displayed a $200 price, a 10mg lyophilized-vial description, and a laboratory-research-only label. Its text describes tirzepatide as a dual GIP/GLP-1 receptor agonist and states that identity and purity are verified using third-party HPLC and mass spectrometry. A certificate of analysis is said to be available on request. All of those testing details are the seller’s published claims; a specific current-lot laboratory certificate was not independently examined for this article. [2] See the published Peptide Sciences quality assurance for the supplier’s current stated procedures. This listing appears on eupeptidesciences.com, the website of the independent EU Peptide Sciences supplier.

The 10mg page also links to Tirzepatide 5mg and 15mg presentations. Those links establish that the seller refers to two other strengths; the corresponding pages did not load consistently during verification, so their current prices, stock status and orderability should not be treated as independently confirmed. The large research peptides catalogue contains a broader product assortment, but a storefront listing does not itself verify warehouse inventory. [2][5] See the published Peptide Sciences research catalogue for the supplier’s current stated procedures.

EU Peptide Sciences says it dispatches from the European Union and provides support for US laboratories. Its posted terms refer to manual payment instructions, a $100 minimum order, tracked shipping, and batch certificates on request. These are stated business policies rather than confirmation that a particular shipment or laboratory result was independently audited. [2][5]

The source-site image at left displays Epithalon, BPC-157, and TB-500

packaging. It is included only as an example of the website’s current

branding; it is not an image of a tirzepatide batch and must not be used to

infer the compound’s authenticity, stock, or purity. [3]

What tirzepatide is – and why researchers study it

Tirzepatide is a 39-amino-acid synthetic peptide that activates two incretin pathways: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). An attached fatty-acid-derived moiety supports albumin binding and helps prolong exposure in approved medicinal formulations. The combination distinguishes tirzepatide from agents that target GLP-1 alone. [2][6]

Laboratories investigate receptor signaling, cAMP responses, comparative agonist activity, pancreatic islet responses, and pharmacologic mechanisms. Those studies have a different purpose from using a manufactured pharmaceutical product in patient care. Evidence generated for Lilly’s approved products cannot be assumed to validate an independent supplier’s vial, even if the label names the same active substance.

Claims about clinical benefits need specific clinical evidence, formulation controls and regulatory review. Likewise, a purity percentage from HPLC alone does not demonstrate sterility, endotoxin status, correct identity or suitability for injection.

Target receptor	Research description
GIP receptor	Incretin signaling pathway.
GLP-1 receptor	Incretin signaling pathway.
Qualification	Conceptual schematic, not a claim of equal potency or clinical equivalence.

 

The FDA distinction: approved medicines are not research vials

Source-article image retained for editorial context; visual appearance is not laboratory verification.

Tirzepatide is not an entirely unapproved ingredient: Mounjaro was initially approved by the FDA for type 2 diabetes in May 2022, and Zepbound was approved in November 2023 for chronic weight management in specified adults. Zepbound later gained an indication for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024. In August 2026, Lilly announced an additional Mounjaro approval for reducing certain major cardiovascular events in adults with type 2 diabetes who have high cardiovascular risk. Each decision applies to an identified prescription drug and indication. [6][7][8][9]

A product described as “Tirzepatide 10mg – laboratory research only” is not converted into Mounjaro or Zepbound by carrying the same generic ingredient name. Regulatory approval, manufacturer controls, presentation, prescribing conditions, and distribution requirements are distinct. The commercial research listing is not evidence of FDA approval or legal permission to supply the material for human treatment.

The FDA warns that unapproved tirzepatide may be counterfeit, misbranded or contaminated and that sellers sometimes use “research purposes” or “not for human consumption” wording even where products are really being marketed for human use. The agency urges patients to obtain prescription medicines from licensed pharmacies. [10]

Comparison point	FDA-approved medicine	Independent research listing
What is reviewed?	Named manufacturer, formulation, indications, quality system and labeling.	Seller-published product specifications; FDA review is not established.
Intended setting	Prescription use under an approved indication.	Laboratory research claim; not authorized as a medicine.
Evidence standard	Agency-reviewed safety, efficacy and quality dossier.	Batch COA and laboratory testing require verification and do not replace FDA approval.

What changed in the wider US tirzepatide market

The FDA reaffirmed in December 2024 that the national shortage of tirzepatide injections was resolved, and subsequent litigation and enforcement-discretion timelines in 2025 affected certain compounding activities. Its April 2026 guidance reiterated that tirzepatide was not on the FDA drug-shortage list or the 503B bulk-substances list and that compounded copies of commercially available drugs face statutory restrictions. This is policy context, not a verified explanation for Peptide Sciences’ business decisions. [11]

In February 2026 the FDA also announced plans to increase scrutiny of non-approved GLP-1 active ingredients promoted as alternatives to approved medicines. FDA statements emphasize that compounded products, when allowed, do not undergo the same agency premarket review as approved drugs. The exact legality of an individual laboratory sale depends on product intent, promotional claims, buyer, distribution and other facts, not on a disclaimer alone. [12][10]

For a research organization, the prudent response is to obtain institutional purchasing and regulatory review before treating a commercial listing as eligible for shipment, import or use in the United States.

How to evaluate the EU site’s quality documentation

EU Peptide Sciences describes a multi-stage quality process on its quality assurance standards page, including outside analytical testing and certificates of analysis. Its Peptide Sciences manufacturing standards page describes supplier qualification, release controls, and traceability. These published descriptions are relevant due-diligence material, but a policy page does not verify a particular lot in isolation. [13][14]

A useful certificate check starts with identity: does the document name tirzepatide, identify the testing laboratory, specify methods and dates, and show the same batch or lot reference as the vial? For HPLC, ask what purity measurement and impurity profiling mean in context. For mass spectrometry, look for evidence supporting molecular identity. Institutions evaluating materials for a particular protocol may also need separate information on assay specificity, peptide content, microbial status and storage history.

An on-site star rating or a historical “verified owner” comment is not a substitute for a traceable analytical certificate, nor does a certificate alone authorize human administration. The published EU page says the current batch document can be requested; this article has not inspected a certificate for the active Tirzepatide 10mg listing. [2]

Ownership and independence: what readers should know

EU Peptide Sciences operates an independent research-supply website at eupeptidesciences.com and advertises EU dispatch with US service. It is distinct from the former peptidesciences.com retailer, which has ended sales and expressly rejects outside successor claims. Similar naming and product categories do not establish shared ownership or a business transfer. [1][15]

Readers can verify that the independent EU website is live and its Tirzepatide 10mg listing exists. Neither a functioning storefront nor keyword similarity makes it the former company’s official website. Research institutions should independently verify the contracting entity, batch provenance and applicable rules.

Common questions about Peptide Sciences tirzepatide in 2026

Does the original peptidesciences.com still sell tirzepatide? Its public homepage says operations and research-product sales have been discontinued. A working original tirzepatide checkout has not been verified. [1]

Is there a Tirzepatide 10mg page on eupeptidesciences.com? Yes. A live product page displays a $200 listed price and research-only language as of 8 October 2026. A listing is not proof of current stock or laboratory test results. [2]

Are 5mg and 15mg EU listings verified? The 10mg page links to these presentations, but their individual pages did not load reliably during checking, so price and inventory are unconfirmed. [2]

Why did Peptide Sciences stop selling tirzepatide? The legacy domain has not publicly provided a compound-specific reason in the material reviewed. Broader FDA enforcement changes should not be presented as a proven cause. [1][11]

Is tirzepatide FDA-approved? The active ingredient is approved in named prescription medicines, including Mounjaro and Zepbound, for their respective indications. Independent research vials are not thereby approved. [6][7]

Does “research use only” make a product lawful for human use? No. FDA has specifically warned about unapproved tirzepatide marketed under research-only labels when offered for human use. [10]

Does HPLC confirm that a vial is safe for injection? No. HPLC purity can be informative but is not equivalent to identity, sterility, endotoxin testing, validated manufacturing, clinical suitability or regulatory approval.

Is EU Peptide Sciences the old company’s official successor? No. EU Peptide Sciences is described here as an independent supplier, not an affiliate or successor of the discontinued peptidesciences.com business. [1][15]

Final perspective

Searches for ‘Peptide Sciences tirzepatide’ can refer to the original closed retailer or to the separate EU Peptide Sciences catalogue. The independently operated eupeptidesciences.com website advertised a Tirzepatide 10mg research listing and links to other strengths; those listings are not approved medicines. Readers should distinguish two businesses, verify batch documentation, and follow the applicable regulatory rules.

Sources and verification notes

Claims were cross-checked against live primary-source pages on 8 October 2026. References to “website reports” describe seller statements; they are not independent quality audits. [A] refers to the supplied Ahrefs US keyword exports.

[1] Peptide Sciences original shutdown notice

[2] EU Peptide Sciences Tirzepatide 10mg listing

[3] EU Peptide Sciences homepage and sample branded image

[4] FDA drug approvals and research-product distinction

[5] EU Peptide Sciences shop catalogue

[6] FDA Mounjaro original approval and trial snapshot

[7] FDA approval of Zepbound for chronic weight management

[8] FDA approval of Zepbound for obstructive sleep apnea

[9] Lilly August 2026 Mounjaro cardiovascular indication announcement

[10] FDA concerns with unapproved GLP-1 medicines and research labels

[11] FDA compounding and tirzepatide shortage policy timeline

[12] FDA February 2026 unapproved GLP-1 enforcement statement

[13] EU Peptide Sciences quality assurance page

[14] EU Peptide Sciences manufacturing standards page

[15] EU Peptide Sciences about page

[A] User-supplied Ahrefs matching-terms exports (United States), dated 8 October 2026. Search-volume estimates are not real traffic measurements.

How evidence was classified Primary-source fact: A statement directly displayed by the original Peptide Sciences domain or by a US regulator. Seller-reported fact: A current catalogue entry, policy, or testing assertion on eupeptidesciences.com; an actual lot certificate or completed transaction was not verified. Unresolved: An historical listing removal date or any disputed ownership transfer unsupported by public corroboration.

The Ahrefs export was used only to identify query interest, not to establish the truth of any business or clinical claim. AI-generated laboratory artwork is illustrative; the example EU-site product photograph shows other compounds and is explicitly identified as such.

Research-use discussion only. This article is not medical or legal advice, and does not recommend self-administering laboratory materials.

Linked supporting references

The following URLs appeared as hyperlinks in the source PDF and are retained for reference. They are not endorsements.

eupeptidesciences.com / about us

peptidesciences.com /

fda.gov / fdas concerns unapproved glp 1 drugs used weight loss

fda.gov / drug trials snapshots mounjaro

fda.gov / fda approves new medication chronic weight management

fda.gov / fda approves first medication obstructive sleep apnea

investor.lilly.com / fda approves lillys mounjaro tirzepatide reduce cardiovascular

fda.gov / fda clarifies policies compounders national glp 1 supply begins stabilize

fda.gov / fda intends take action against non fda approved glp 1 drugs